Assessing healthy vaccinee effect in COVID-19 vaccine effectiveness studies: a national cohort study in Qatar. Academic Article uri icon

Overview

abstract

  • BACKGROUND: This study investigated the presence of the healthy vaccinee effect-the imbalance in health status between vaccinated and unvaccinated individuals-in two rigorously conducted COVID-19 vaccine effectiveness studies involving primary series and booster vaccinations. It also examined the temporal patterns and variability of this effect across different subpopulations by analyzing the association between COVID-19 vaccination and non-COVID-19 mortality in Qatar. METHODS: Two matched, retrospective cohort studies assessed the incidence of non-COVID-19 death in national cohorts of individuals with a primary series vaccination versus no vaccination (two-dose analysis), and individuals with three-dose (booster) vaccination versus primary series vaccination (three-dose analysis), from January 5, 2021, to April 9, 2024. RESULTS: The adjusted hazard ratio (aHR) for non-COVID-19 death was 0.76 (95% CI: 0.64-0.90) in the two-dose analysis and 0.85 (95% CI: 0.67-1.07) in the three-dose analysis. In the first 6 months of follow-up in the two-dose analysis, the aHR was 0.35 (95% CI: 0.27-0.46); however, the combined analysis of all subsequent periods showed an aHR of 1.52 (95% CI: 1.19-1.94). In the first 6 months of follow-up in the three-dose analysis, the aHR was 0.31 (95% CI: 0.20-0.50); however, the combined analysis of all subsequent periods showed an aHR of 1.37 (95% CI: 1.02-1.85). The overall effectiveness of the primary series and third-dose vaccinations against severe, critical, or fatal COVID-19 was 95.9% (95% CI: 94.0-97.1) and 34.1% (95% CI: -46.4-76.7), respectively. Subgroup analyses showed that the healthy vaccinee effect is pronounced among those aged 50 years and older and among those more clinically vulnerable to severe COVID-19. CONCLUSIONS: A pronounced healthy vaccinee effect was observed during the first 6 months following vaccination, despite meticulous cohort matching. This effect may have stemmed from a lower likelihood of vaccination among seriously ill, end-of-life individuals, and less mobile elderly populations. FUNDING: Biomedical Research Program and the Biostatistics, Epidemiology, and Biomathematics Research Core, and Junior Faculty Transition to Independence Program, all at Weill Cornell Medicine-Qatar, Qatar University, Ministry of Public Health, Hamad Medical Corporation, Sidra Medicine, Qatar Genome Programme, Qatar University Biomedical Research Center, and L'OrĂ©al-UNESCO For Women In Science Middle East Regional Young Talents Program.

authors

  • Chemaitelly, Hiam Souheil
  • Ayoub, Houssein H
  • Coyle, Peter
  • Tang, Patrick
  • Hasan, Mohammad R
  • Yassine, Hadi M
  • Al Thani, Asmaa A
  • Al-Kanaani, Zaina
  • Al-Kuwari, Einas
  • Jeremijenko, Andrew
  • Kaleeckal, Anvar Hassan
  • Latif, Ali Nizar
  • Shaik, Riyazuddin Mohammad
  • Abdul-Rahim, Hanan F
  • Nasrallah, Gheyath K
  • Al-Kuwari, Mohamed Ghaith
  • Al-Romaihi, Hamad Eid
  • Al-Thani, Mohamed H
  • Al-Khal, Abdullatif
  • Bertollini, Roberto
  • Butt, Adeel A
  • Abu-Raddad, Laith Jamal

publication date

  • June 9, 2025

Research

keywords

  • COVID-19
  • COVID-19 Vaccines
  • Vaccine Efficacy

Identity

PubMed Central ID

  • PMC12148324

Digital Object Identifier (DOI)

  • 10.7554/eLife.103690

PubMed ID

  • 40488740

Additional Document Info

volume

  • 14